Whereas sickle cell disease is the most common inherited blood disorder in the United States, affecting approximately 100,000 people in the United States; Whereas more than 3,000,000 people in the United States have the sickle cell trait, and many are unaware of their status; Whereas, in 2010, the total number of babies born with sickle cell trait was estimated to have exceeded 60,000, and the total United States incidence estimate was 15.5 cases per 1,000 births; Whereas sickle cell disease occurs in about 1 out of every 365 Black or African-American births and 1 out of every 16,300 Hispanic-American births; Whereas individuals who have sickle cell trait have a 50-percent chance of passing on the abnormal sickle cell gene to future offspring and a 25-percent chance of having future children with sickle cell disease if both parents have the trait; Whereas sickle cell disease can be identified before birth by testing a sample of amniotic fluid or tissue from the placenta; Whereas individuals with sickle cell trait have the same life expectancy as the general population, but are at risk for certain conditions, including blood in the urine, kidney cancer, complications with trauma to the eye, and tissue death in the spleen at high altitudes, or may have a false positive A1C test; Whereas, during the 115th Congress, Public Law 115–327 reauthorized a sickle cell disease prevention and treatment demonstration program and provided for sickle cell research, surveillance, prevention, and treatment; Whereas following the enactment of Public Law 115–327 , the National Institutes of Health launched the Cure Sickle Cell Initiative aimed at bringing genetic therapies into first-in-human clinical trials within 5 years and moving newly developed genetic therapies, including gene-editing approaches, into clinical research